Skip to content

Sarepta Therapeutics’ Orphan Drug Eteplirsen For Duchenne Muscular Dystrophy: Perspective

October 18, 2012

       An October 17, 2012 article gives a fresh perspective on Sarepta Therapeutics’ orphan drug Eteplirsen for Duchenne Muscular Dystrophy (DMD).’s article identifies upcoming key catalysts : 

1)  Investor call with DMD expert Dr. David McDonald (October 17, 2012) 

2)  Investor call with Sarepta Therapeutics CEO Chris Garabedian & CMO Ed Kaye (October 18, 2012) 

3)  Sarepta Therapeutics’ post Phase II meeting with the FDA either late 2012 or early 2013 

4)  Additional 6MWT data may become available in December 2012 – at 60 weeks. 

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: